The move is part of Eisai China’s goal to bolster the production efficiency and stable supply chain of quality pharmaceuticals in the country by building an industrial site that would be five times larger than the existing Suzhou Plant with an OSD manufacturing facility.
The new facility will see formulation and packaging of oral solid dose products such as Methycobal, Aricept and Pariet for the domestic market of the country.
With a floor space of around 20,240m², the production capacity of the building is said to be double to that of the current plant, accounting to formulation of approximately three billion tablets or packaging for five billion tablets annually.
The facility is expected to begin work in the second half of fiscal 2018, and the firm intends to close the existing plant after the operations are fully commenced.
In addition to the new OSD production facility, the new 134,000m² Suzhou Plant includes a parenteral production facility constructed in 2014 to manufacture products such as Methycobal injection.
The 2,230m² administrative building has been designed to include spaces for offices, meeting rooms and cafeteria.
Eisai recently obtained breakthrough therapy designation for its multiple receptor tyrosine kinase inhibitor LENVIMA in combination with Merck’s anti-PD-1 therapy KEYTRUDA to potentially treat advanced and/or metastatic renal cell carcinoma.